Article citationsMore>>
E. Maraskovsky, S. Sjolander, D. P. Drane, M. Schnurr, T. T. Le, L. Mateo, T. Luft, K. A. Masterman, T. Y. Tai, Q. Chen, S. Green, A. Sjolander, M. J. Pearse, F. A. Lemonnier, W. Chen, J. Cebon and A. Suhrbier, “NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors,” Clinical Cancer Research, Vol. 10, No. 8, 2004, pp. 2879-2890.
doi:10.1158/1078-0432.CCR-03-0245
has been cited by the following article:
-
TITLE:
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
AUTHORS:
Kristian M. Hargadon
KEYWORDS:
Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer
JOURNAL NAME:
Journal of Cosmetics, Dermatological Sciences and Applications,
Vol.3 No.2A,
June
20,
2013
ABSTRACT:
Melanoma is the most aggressive form
of skin cancer and accounts for the vast majority of skin cancer-related
deaths. Its ability to metastasize quickly, often before diagnosis, makes this
cancer difficult to treat with traditional therapies. The identification of
anti-melanoma immune responses in patients and the discovery of tumor antigens
targeted by these immune responses have paved the way for immunotherapy as a
novel approach to treating this cancer. In this review, the major
immunotherapies targeting these melanoma tumor antigens are discussed. The
advantages and limitations of peptide-, protein-, and gene-based vaccination
maneuvers and adoptive cell transfer therapies are emphasized. Recent insights
into melanoma immune evasion strategies are also highlighted, with particular
focus on how our increasing knowledge of tumor/immune cell interactions is
driving the development of novel immunotherapeutic strategies for the treatment
of melanoma.
Related Articles:
-
Om Parkash
-
R. Douglas Martin, Shengyu Zhang
-
Daniel T. Cassidy
-
Sopita Khamrod
-
Daoling Fu, Ming Yang, Jindong Chang